Breast cancer patients treated with paclitaxel-based chemotherapy and radiation therapy do not experience pneumonitis--an inflammation of lung tissue--more often than patients treated with ...

Controlling for whether hospitals were high- versus low-volume users of paclitaxel devices did not change the results. Further, use of falsification endpoints (acute MI, congestive HF, and pneumonia) ...

Authors present feasibility pilot study results of dose-dense epirubicin/cyclophosphamide and paclitaxel with pegfilgrastim for breast cancer.

Background: In 2001, Taghian et al (JNCI 2001;93:1806–11) published a retrospective cohort study of 41 breast cancer patients treated with adjuvant paclitaxel and radiotherapy (RT). The crude rate of ...

ENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive Unresectable or ... Interstitial lung disease (ILD) and ...

e17507 Background: Synchronizing low-dose paclitaxel with timed daily RT achieves remarkable local tumor response by inducing maximum radio sensitization through G2-M cell cycle arrest and apoptosis ...

Topline data were announced from a phase 2/3 trial evaluating tovecimig in combination with paclitaxel in patients with unresectable advanced, metastatic or recurrent biliary tract cancers (BTC).

It is generally accepted that paclitaxel-eluting stents are inferior to limus-eluting stents in most patients with coronary artery disease. One exception is patients with diabetes, for whom ...

From December 2001 through May 2004, a total of 722 patients were enrolled. Paclitaxel plus bevacizumab significantly prolonged progression-free survival as compared with paclitaxel alone (median ...